Texting to Promote Tobacco Abstinence in Emergency Department Smokers: A Pilot Study
NCT ID: NCT02081144
Last Updated: 2020-03-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
60 participants
INTERVENTIONAL
2014-05-31
2014-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optimizing Tobacco Dependence Treatment in the Emergency Department
NCT02896400
Text Messaging for Smoking Cessation in College Health Clinics
NCT02191033
A Text Messaging Program for Smokers in Primary Care
NCT03174158
Treating Low-Income Smokers in the Hospital Emergency Department
NCT01328431
Penn State TXT2STAYQUIT Study- a Texting Study to Help Hospitalized Smokers Stay Quit
NCT02986711
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control Condition
Control or Standard Care condition. No intervention will be provided.
No interventions assigned to this group
Texting + NRT Condition
Enrollment in NCI's Smokefree TXT Program 4 weeks of Nicotine Replacement Patches 4 weeks of Nicotine Replacement Gum Faxed Referral CT Smokers Quitline
Smokefree TXT Program
The SmokeFreeTxt program is a library consisting of \~130 brief messages that can be proactively sent to smokers' cellphones using software developed and maintained by NCI. The message content is informed by principles of cognitive behavioral therapy. They are sent to smokers at random times of day (during normal waking hours), up to 5 messages per day.
nicotine replacement patches
Subject will be given 4 weeks of Nicotine Replacement Patches, based on the amount he/she is smoking at baseline.
Nicotine Replacement Gum
Subjects will be given 10 pieces of 2mg Nicotine Replacement Gum x 28 days.
Faxed Referral CT Smokers Quitline
A faxed referral will be sent to the CT Smokers Quitline for the subject.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Smokefree TXT Program
The SmokeFreeTxt program is a library consisting of \~130 brief messages that can be proactively sent to smokers' cellphones using software developed and maintained by NCI. The message content is informed by principles of cognitive behavioral therapy. They are sent to smokers at random times of day (during normal waking hours), up to 5 messages per day.
nicotine replacement patches
Subject will be given 4 weeks of Nicotine Replacement Patches, based on the amount he/she is smoking at baseline.
Nicotine Replacement Gum
Subjects will be given 10 pieces of 2mg Nicotine Replacement Gum x 28 days.
Faxed Referral CT Smokers Quitline
A faxed referral will be sent to the CT Smokers Quitline for the subject.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* have smoked \>= 100 cigarettes lifetime
* describe themselves as every or some day smokers
* are able to give written informed consent
* reside in Connecticut
* own a cell phone with texting capability.
Exclusion Criteria
* currently receiving formal tobacco dependence treatment
* current use of tobacco cessation products (patch, gum, inhaler, nasal spray, lozenge, e-cigarette)
* currently using Zyban (bupropion), Wellbutrin (bupropion) or Chantix (varenicline) for smoking cessation
* current suicide or homicide risk
* current psychotic disorder
* life-threatening or unstable medical or psychiatric condition
* does not have phone with CT area code and with texting capability
* lacks capacity to give informed consent
* leaving the ED against medical advice
* pregnant, nursing, or trying to conceive
* incarcerated
* resides in an extended care facility
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
National Institutes of Health (NIH)
NIH
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steven L Bernstein, MD
Role: PRINCIPAL_INVESTIGATOR
Yale University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yale New Haven Hospital
New Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1401013302
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.